AU2021296151A1 - Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib - Google Patents

Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib Download PDF

Info

Publication number
AU2021296151A1
AU2021296151A1 AU2021296151A AU2021296151A AU2021296151A1 AU 2021296151 A1 AU2021296151 A1 AU 2021296151A1 AU 2021296151 A AU2021296151 A AU 2021296151A AU 2021296151 A AU2021296151 A AU 2021296151A AU 2021296151 A1 AU2021296151 A1 AU 2021296151A1
Authority
AU
Australia
Prior art keywords
rcc
cancer
lenvatinib
hif
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021296151A
Other languages
English (en)
Inventor
Rodolfo Fleury Perini
Elaine M. Pinheiro
Jaqueline WILLEMANN ROGERIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Merck Sharp & Dohme LLC
Original Assignee
Eisai R&D Management Co Ltd
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd, Merck Sharp & Dohme LLC filed Critical Eisai R&D Management Co Ltd
Publication of AU2021296151A1 publication Critical patent/AU2021296151A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021296151A 2020-06-22 2021-06-21 Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib Pending AU2021296151A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US63/042,307 2020-06-22
US202163146915P 2021-02-08 2021-02-08
US63/146,915 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (1)

Publication Number Publication Date
AU2021296151A1 true AU2021296151A1 (en) 2023-02-02

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021296151A Pending AU2021296151A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib

Country Status (11)

Country Link
US (1) US20230210838A1 (cg-RX-API-DMAC7.html)
EP (2) EP4168008B1 (cg-RX-API-DMAC7.html)
JP (1) JP7750884B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230026493A (cg-RX-API-DMAC7.html)
CN (1) CN115803629A (cg-RX-API-DMAC7.html)
AU (1) AU2021296151A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026094A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183852A1 (cg-RX-API-DMAC7.html)
ES (1) ES3072250T3 (cg-RX-API-DMAC7.html)
MX (2) MX2022016406A (cg-RX-API-DMAC7.html)
WO (1) WO2021262563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
US20240327929A1 (en) * 2021-08-12 2024-10-03 Merck Sharp & Dohme Llc Dosage regimen for administration of belzutifan
EP4425678A1 (en) 2023-02-28 2024-09-04 LG Energy Solution, Ltd. Separator for electrochemical device and electrochemical device comprising same
JPWO2024204679A1 (cg-RX-API-DMAC7.html) * 2023-03-31 2024-10-03

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
EP3866927A4 (en) * 2018-10-17 2022-07-27 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Also Published As

Publication number Publication date
MX2022016406A (es) 2023-01-30
MX2025014865A (es) 2026-01-07
EP4168008A4 (en) 2024-08-07
EP4775271A2 (en) 2026-07-15
BR112022026094A2 (pt) 2023-01-17
CN115803629A (zh) 2023-03-14
ES3072250T3 (en) 2026-06-30
JP2023531675A (ja) 2023-07-25
JP7750884B2 (ja) 2025-10-07
KR20230026493A (ko) 2023-02-24
EP4168008A1 (en) 2023-04-26
EP4168008B1 (en) 2026-03-18
CA3183852A1 (en) 2021-12-30
WO2021262563A1 (en) 2021-12-30
US20230210838A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
Reardon et al. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges
Bendell et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
US20230181565A1 (en) Crenolanib combination therapy
EP3721906A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
Scaringi et al. Combining molecular targeted agents with radiation therapy for malignant gliomas
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2023100070A1 (en) Cdk4 inhibitor for the treatment of cancer
JP2023531683A5 (cg-RX-API-DMAC7.html)
EP4168016A2 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
WO2021262562A2 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
JP7308145B2 (ja) 固形腫瘍を治療するための医薬組成物
Carrato et al. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer
HK40087480A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib
US20210113692A1 (en) Dosing regimen
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
Wagner Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs
US20180104234A1 (en) Combination therapy for cancer
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、P-gp阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
WO2026037393A1 (zh) 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合
Theodore et al. Topoisomerase Therapy in
Wu et al. Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents
WO2023078408A1 (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用